These data are in line with a very recent study suggesting that BTK inhibition actually sensitizes macrophages to TLR-4-induced NLRP3 activation and promotes injury-induced organ inflammation17 indicating to refrain from the use of ibrutinib, and probably BTK inhibitors in the treatment of AKI. This evidence concerns the gene BTK and acute kidney injury.